Several studies have reported that certain HLA/KIR combinations are associated with susceptibility and worse clinical outcomes and response to treatment in several types of cancer, including breast cancer, colorectal cancer and lung cancer 12-18. This evidence concerns the gene KIR3DL1 and lung carcinoma.